Novo Nordisk is investing $4.1 billion to construct a new manufacturing plant in Clayton, North Carolina, to meet the high demand for their weight loss drug Wegovy and diabetes treatment Ozempic. The investment is part of a larger $6.8 billion production plan for the year to address supply shortages in the U.S. The new facility will produce syringes and injection pens for the drugs and will employ 1,000 workers, adding to the company's existing workforce in North Carolina. Novo Nordisk currently has two operational sites in Clayton and one in Durham, with additional facilities in New Hampshire and overseas. The company is taking a deliberate approach to releasing lower doses of Wegovy to ensure existing patients can maintain treatment. Competitor Eli Lilly is also expanding manufacturing capacity for their GLP-1 medications.